Herpesviruses reactivation following COVID-19 vaccination: a systematic review and meta-analysis.
Humans
BNT162 Vaccine
ChAdOx1 nCoV-19
COVID-19
/ prevention & control
COVID-19 Vaccines
/ adverse effects
Cytomegalovirus
/ genetics
Cytomegalovirus Infections
Epstein-Barr Virus Infections
Herpesviridae Infections
Herpesvirus 3, Human
/ genetics
Herpesvirus 4, Human
/ genetics
Simplexvirus
Vaccination
/ adverse effects
Viruses
COVID-19
HHV
Herpesvirus
SARS-CoV-2
Vaccination
Journal
European journal of medical research
ISSN: 2047-783X
Titre abrégé: Eur J Med Res
Pays: England
ID NLM: 9517857
Informations de publication
Date de publication:
10 Aug 2023
10 Aug 2023
Historique:
received:
15
01
2023
accepted:
19
07
2023
medline:
11
8
2023
pubmed:
10
8
2023
entrez:
9
8
2023
Statut:
epublish
Résumé
The reactivation of herpesviruses (HHV) in COVID-19 patients is evident in the literature. Several reports have been published regarding the reactivation of these viruses (HSV, VZV, EBV, and CMV) among those who got COVID-19 vaccines. In this study, we aimed to review the current evidence to assess whether HHVs reactivation has any association with the prior administration of COVID-19 vaccines. A systematic search was conducted on 25 September 2022 in PubMed/MEDLINE, Web of Science, and EMBASE. We included all observational studies, case reports, and case series which reported the reactivation of human herpesviruses following administration of COVID-19 vaccines. Our systematic search showed 80 articles that meet the eligibility criteria. Among the evaluated COVID-19 vaccines, most of the vaccines were mRNA based. Evidence from observational studies showed the possible relation between COVID-19 vaccine administration and VZV and HSV reactivation. The results of our proportion meta-analysis showed that the rate of VZV reactivation among those who received the COVID-19 vaccine was 14 persons per 1000 vaccinations (95% CI 2.97-32.80). Moreover, our meta-analysis for HSV reactivation showed the rate of 16 persons per 1000 vaccinations (95% CI 1.06-46.4). Furthermore, the evidence from case reports/series showed 149 cases of HHV reactivation. There were several vaccines that caused reactivation including BNT162b2 mRNA or Pfizer-BioNTech (n = 76), Oxford-AstraZeneca (n = 22), mRNA-1273 or Moderna (n = 17), Sinovac (n = 4), BBIBP-CorV or Sinopharm (n = 3), Covaxin (n = 3), Covishield (n = 3), and Johnson and Johnson (n = 1). Reactivated HHVs included varicella-zoster virus (VZV) (n = 114), cytomegalovirus (CMV) (n = 15), herpes simplex virus (HSV) (n = 14), Epstein-Barr virus (EBV) (n = 6), and HHV-6 (n = 2). Most cases reported their disease after the first dose of the vaccine. Many patients reported having comorbidities, of which hypertension, diabetes mellitus, dyslipidemia, chicken pox, and atrial fibrillation were common. In conclusion, our study showed the possible association between COVID-19 vaccination and herpesvirus reactivation. The evidence for VZV and HSV was supported by observational studies. However, regarding other herpesviruses (EBV and CMV), further research especially from observational studies and clinical trials is required to elucidate the interaction between COVID-19 vaccination and their reactivation.
Sections du résumé
BACKGROUND
BACKGROUND
The reactivation of herpesviruses (HHV) in COVID-19 patients is evident in the literature. Several reports have been published regarding the reactivation of these viruses (HSV, VZV, EBV, and CMV) among those who got COVID-19 vaccines. In this study, we aimed to review the current evidence to assess whether HHVs reactivation has any association with the prior administration of COVID-19 vaccines.
METHODS
METHODS
A systematic search was conducted on 25 September 2022 in PubMed/MEDLINE, Web of Science, and EMBASE. We included all observational studies, case reports, and case series which reported the reactivation of human herpesviruses following administration of COVID-19 vaccines.
RESULTS
RESULTS
Our systematic search showed 80 articles that meet the eligibility criteria. Among the evaluated COVID-19 vaccines, most of the vaccines were mRNA based. Evidence from observational studies showed the possible relation between COVID-19 vaccine administration and VZV and HSV reactivation. The results of our proportion meta-analysis showed that the rate of VZV reactivation among those who received the COVID-19 vaccine was 14 persons per 1000 vaccinations (95% CI 2.97-32.80). Moreover, our meta-analysis for HSV reactivation showed the rate of 16 persons per 1000 vaccinations (95% CI 1.06-46.4). Furthermore, the evidence from case reports/series showed 149 cases of HHV reactivation. There were several vaccines that caused reactivation including BNT162b2 mRNA or Pfizer-BioNTech (n = 76), Oxford-AstraZeneca (n = 22), mRNA-1273 or Moderna (n = 17), Sinovac (n = 4), BBIBP-CorV or Sinopharm (n = 3), Covaxin (n = 3), Covishield (n = 3), and Johnson and Johnson (n = 1). Reactivated HHVs included varicella-zoster virus (VZV) (n = 114), cytomegalovirus (CMV) (n = 15), herpes simplex virus (HSV) (n = 14), Epstein-Barr virus (EBV) (n = 6), and HHV-6 (n = 2). Most cases reported their disease after the first dose of the vaccine. Many patients reported having comorbidities, of which hypertension, diabetes mellitus, dyslipidemia, chicken pox, and atrial fibrillation were common.
CONCLUSION
CONCLUSIONS
In conclusion, our study showed the possible association between COVID-19 vaccination and herpesvirus reactivation. The evidence for VZV and HSV was supported by observational studies. However, regarding other herpesviruses (EBV and CMV), further research especially from observational studies and clinical trials is required to elucidate the interaction between COVID-19 vaccination and their reactivation.
Identifiants
pubmed: 37559096
doi: 10.1186/s40001-023-01238-9
pii: 10.1186/s40001-023-01238-9
pmc: PMC10413536
doi:
Substances chimiques
BBV152 COVID-19 vaccine
76JZE5DSN6
BIBP COVID-19 vaccine
0
BNT162 Vaccine
0
ChAdOx1 nCoV-19
B5S3K2V0G8
COVID-19 Vaccines
0
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
278Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Han F, et al. Current treatment strategies for COVID-19 (Review). Mol Med Rep. 2021. https://doi.org/10.3892/mmr.2021.12498 .
doi: 10.3892/mmr.2021.12498
pubmed: 34878158
pmcid: 8674706
Shafiee A, et al. Ivermectin under scrutiny: a systematic review and meta-analysis of efficacy and possible sources of controversies in COVID-19 patients. Virol J. 2022;19(1):102.
pubmed: 35698151
pmcid: 9191543
doi: 10.1186/s12985-022-01829-8
Cheema HA, et al. No evidence of clinical efficacy of famotidine for the treatment of COVID-19: a systematic review and meta-analysis. J Infect. 2022. https://doi.org/10.1016/j.jinf.2022.11.022 .
doi: 10.1016/j.jinf.2022.11.022
pubmed: 36462586
pmcid: 9711899
Loubet P, et al. A french cohort for assessing COVID-19 vaccine responses in specific populations. Nat Med. 2021;27(8):1319–21.
pubmed: 34253930
doi: 10.1038/s41591-021-01435-1
Pormohammad A, et al. Efficacy and safety of COVID-19 vaccines: a systematic review and meta-analysis of randomized clinical trials. Vaccines (Basel). 2021. https://doi.org/10.3390/vaccines9050467 .
doi: 10.3390/vaccines9050467
pubmed: 35062684
Tavoosian A, Arabzadeh Bahri R, Zahmatkesh P, Khoshchehreh M, Aghsaee Fard Z, Abedi Yarandi V. Safe Medication with Remdesivir for COVID-19 in Patients with Infertility. Translational Research in Urology. 2023 May 1;5(2):89-94.
Suzich JB, Cliffe AR. Strength in diversity: understanding the pathways to herpes simplex virus reactivation. Virology. 2018;522:81–91.
pubmed: 30014861
doi: 10.1016/j.virol.2018.07.011
Ong DSY, et al. Epidemiology of multiple herpes viremia in previously immunocompetent patients with septic shock. Clin Infect Dis. 2017;64(9):1204–10.
pubmed: 28158551
doi: 10.1093/cid/cix120
Simonnet A, et al. High incidence of Epstein-Barr virus, cytomegalovirus, and human-herpes virus-6 reactivations in critically ill patients with COVID-19. Infect Dis Now. 2021;51(3):296–9.
pubmed: 33495765
pmcid: 7816954
doi: 10.1016/j.idnow.2021.01.005
Shafiee A, et al. Epstein-Barr virus and COVID-19. J Med Virol. 2022;94(9):4040–2.
pubmed: 35505635
pmcid: 9348397
doi: 10.1002/jmv.27823
Shafiee A, Teymouri Athar MM, Amini MJ, Hajishah H, Siahvoshi S, Jalali M, Jahanbakhshi B, Mozhgani SH. Reactivation of herpesviruses during COVID-19: A systematic review and meta-analysis. Rev Med Virol. 2023 May;33(3):e2437. https://doi.org/10.1002/rmv.2437 . Epub 2023 Mar 7. PMID: 36880642.
Katsikas Triantafyllidis K, et al. Varicella zoster virus reactivation following COVID-19 vaccination: a systematic review of case reports. Vaccines (Basel). 2021. https://doi.org/10.3390/vaccines9091013 .
doi: 10.3390/vaccines9091013
pubmed: 34579250
Page MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):89.
pubmed: 33781348
pmcid: 8008539
doi: 10.1186/s13643-021-01626-4
Cumpston M, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane database syst reviews. 2019. https://doi.org/10.1002/14651858.ED000142 .
doi: 10.1002/14651858.ED000142
JB Institute. The Joanna Briggs Institute critical appraisal tools for use in JBI systematic review: checklists for case reports. The Joanna Briggs Institute; 2019.
JB Institute. The Joanna Briggs Institute critical appraisal tools for use in JBI systematic reviews. checklist for case series; 2017.
Fazlollahi A, et al. Cardiac complications following mRNA COVID-19 vaccines: a systematic review of case reports and case series. Rev Med Virol. 2022;32(4): e2318.
pubmed: 34921468
doi: 10.1002/rmv.2318
Balduzzi S, Rücker G, Schwarzer G How to perform a meta-analysis with R: a practical tutorial BMJ Ment Health 2019;22:153-160.
Wells, G.A., et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Oxford; 2000.
Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22(4):153–60.
pubmed: 31563865
pmcid: 10231495
doi: 10.1136/ebmental-2019-300117
Birabaharan M, Kaelber DC, Karris MY. Risk of herpes zoster reactivation after messenger RNA COVID-19 vaccination: a cohort study. J Am Acad Dermatol. 2022;87(3):649–51.
pubmed: 34826538
doi: 10.1016/j.jaad.2021.11.025
Català A, et al. Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases. Br J Dermatol. 2022;186(1):142–52.
pubmed: 34254291
doi: 10.1111/bjd.20639
Cebeci Kahraman F, et al. Cutaneous reactions after COVID-19 vaccination in Turkey: a multicenter study. J Cosmet Dermatol. 2022;21(9):3692–703.
pubmed: 35780311
doi: 10.1111/jocd.15209
Hertel M, et al. Real-world evidence from over one million COVID-19 vaccinations is consistent with reactivation of the varicella-zoster virus. J Eur Acad Dermatol Venereol: JEADV. 2022;36(8):1342–8.
pubmed: 35470920
doi: 10.1111/jdv.18184
Lee TJ, Lu CH, Hsieh SC. Herpes zoster reactivation after mRNA-1273 vaccination in patients with rheumatic diseases. Ann Rheum Dis. 2022;81(4):595–7.
pubmed: 34876461
doi: 10.1136/annrheumdis-2021-221688
Préta LH, et al. Association study between herpes zoster reporting and mRNA COVID-19 vaccines (BNT162b2 and mRNA-1273). Br J Clin Pharmacol. 2022;88(7):3529–34.
pubmed: 35174524
doi: 10.1111/bcp.15280
Machado PM, et al. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Ann Rheum Dis. 2022;81(5):695–709.
pubmed: 34972811
doi: 10.1136/annrheumdis-2021-221490
Gringeri M, et al. Herpes zoster and simplex reactivation following COVID-19 vaccination: new insights from a vaccine adverse event reporting system (VAERS) database analysis. Expert Rev Vaccines. 2022;21(5):675–84.
pubmed: 35191364
doi: 10.1080/14760584.2022.2044799
Florea A, et al. Risk of herpes zoster following mRNA COVID-19 vaccine administration. Expert Rev Vaccines. 2023;22(1):643–9.
pubmed: 37416973
doi: 10.1080/14760584.2023.2232451
Fathy RA, et al. Varicella-zoster and herpes simplex virus reactivation post-COVID-19 vaccination: a review of 40 cases in an international dermatology registry. J Eur Acad Dermatol Venereol. 2022;36(1):e6–9.
pubmed: 34487581
doi: 10.1111/jdv.17646
Chen J, et al. Varicella zoster virus reactivation following COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a cross-sectional Chinese study of 318 cases. J Med Virol. 2023;95(1): e28307.
pubmed: 36372774
doi: 10.1002/jmv.28307
Zheng F, Willis A, Kunjukunju N. Acute retinal necrosis from reactivation of varicella zoster virus following BNT162b2 mRNA COVID-19 vaccination. Ocul Immunol Inflamm. 2022;30(5):1133–5.
pubmed: 34851795
doi: 10.1080/09273948.2021.2001540
Zhang LW, et al. Disseminated herpes zoster following inactivated SARS-CoV-2 vaccine in a healthy old man. Eur J dermatol: EJD. 2022;32(3):415–6.
pubmed: 36065551
doi: 10.1684/ejd.2022.4286
You IC, Ahn M, Cho NC. A case report of herpes zoster ophthalmicus and meningitis after COVID-19 vaccination. J Korean Med Sci. 2022;37(20): e165.
pubmed: 35607743
pmcid: 9127426
doi: 10.3346/jkms.2022.37.e165
Wang CS, Chen HH, Liu SH. Pityriasis Rosea-like eruptions following COVID-19 mRNA-1273 vaccination: a case report and literature review. J Formos Med Assoc. 2022;121(5):1003–7.
pubmed: 35012825
pmcid: 8731224
doi: 10.1016/j.jfma.2021.12.028
van Dam CS, et al. Herpes zoster after COVID vaccination. Int J Infect Dis. 2021;111:169–71.
pubmed: 34428545
pmcid: 8379763
doi: 10.1016/j.ijid.2021.08.048
Vallianou NG, et al. Herpes zoster following COVID-19 vaccination in an immunocompetent and vaccinated for herpes zoster adult: a two-vaccine related event? Metabol Open. 2022;13: 100171.
pubmed: 35169692
pmcid: 8830150
doi: 10.1016/j.metop.2022.100171
Tripathy DM, et al. Postherpetic granulomatous dermatitis and herpes zoster necroticans triggered by Covid-19 vaccination. Dermatol Ther. 2022;35(10): e15707.
pubmed: 35811450
doi: 10.1111/dth.15707
Thonginnetra S, Limtanyakul P, Tawinprai K. Herpes zoster after COVID-19 vaccination in an adolescent. Dermatol online J. 2022. https://doi.org/10.5070/D328458533 .
doi: 10.5070/D328458533
pubmed: 36259868
Thimmanagari K, et al. Ipsilateral zoster ophthalmicus post COVID-19 vaccine in healthy young adults. Cureus. 2021;13(7): e16725.
pubmed: 34471577
pmcid: 8402883
Tanizaki R, Miyamatsu Y. Zoster sine herpete following BNT162b2 mRNA COVID-19 vaccination in an immunocompetent patient. IDCases. 2022;29: e01563.
pubmed: 35855938
pmcid: 9276537
doi: 10.1016/j.idcr.2022.e01563
Tang WR, et al. A case report of posttransplant lymphoproliferative disorder after astrazeneca coronavirus disease 2019 vaccine in a heart transplant recipient. Transplant Proc. 2022;54(6):1575–8.
pubmed: 34702598
doi: 10.1016/j.transproceed.2021.09.006
Tang LV, Hu Y. Hemophagocytic lymphohistiocytosis after COVID-19 vaccination. J Hematol Oncol. 2021;14(1):87.
pubmed: 34088334
pmcid: 8177256
doi: 10.1186/s13045-021-01100-7
Singh J, et al. Herpes simplex virus retinitis following ChAdOx1 nCoV- 19 (Covishield) vaccination for SARS CoV 2: a case report. Ocul Immunol Inflamm. 2022;30(5):1282–5.
pubmed: 35587646
doi: 10.1080/09273948.2022.2069127
Santovito LS, Pinna G. A case of reactivation of varicella-zoster virus after BNT162b2 vaccine second dose? Inflamm Res. 2021;70(9):935–7.
pubmed: 34390376
pmcid: 8364300
doi: 10.1007/s00011-021-01491-w
Sangoram R, et al. Herpes simplex virus 1 anterior uveitis following coronavirus disease 2019 (COVID-19) vaccination in an asian indian female. Ocul Immunol Inflamm. 2022;30(5):1260–4.
pubmed: 35404741
doi: 10.1080/09273948.2022.2055580
Said JT, et al. Disseminated varicella-zoster virus infections following messenger RNA-based COVID-19 vaccination. JAAD Case Rep. 2021;17:126–9.
pubmed: 34568532
pmcid: 8450136
doi: 10.1016/j.jdcr.2021.09.008
Ryu KJ, Kim DH. Recurrence of varicella-zoster virus keratitis after SARS-CoV-2 vaccination. Cornea. 2022;41(5):649–50.
pubmed: 35383620
doi: 10.1097/ICO.0000000000002999
Poudel S, et al. Bell’s palsy as a possible complication of mRNA-1273 (Moderna) vaccine against COVID-19. Ann Med Surg (Lond). 2022;78: 103897.
pubmed: 35663122
Plüß M, et al. Case report: cytomegalovirus reactivation and pericarditis following ChAdOx1 nCoV-19 vaccination against SARS-CoV-2. Front Immunol. 2021;12: 784145.
pubmed: 35116025
doi: 10.3389/fimmu.2021.784145
Pedrazini MC, da Silva MH. Pityriasis rosea-like cutaneous eruption as a possible dermatological manifestation after Oxford-AstraZeneca vaccine: case report and brief literature review. Dermatol Ther. 2021;34(6): e15129.
pubmed: 34533265
pmcid: 8646511
doi: 10.1111/dth.15129
Papasavvas I, de Courten C, Herbort CP Jr. Varicella-zoster virus reactivation causing herpes zoster ophthalmicus (HZO) after SARS-CoV-2 vaccination - report of three cases. J Ophthalmic Inflamm Infect. 2021;11(1):28.
pubmed: 34529153
pmcid: 8443850
doi: 10.1186/s12348-021-00260-4
Palanivel JA. Herpes zoster after COVID-19 vaccination-Can the vaccine reactivate latent zoster virus? J Cosmet Dermatol. 2021;20(11):3376–7.
pubmed: 34559453
pmcid: 8662047
doi: 10.1111/jocd.14470
Özdemir AK, Kayhan S, Çakmak SK. Herpes zoster after inactivated SARS-CoV-2 vaccine in two healthy young adults. J Eur Acad Dermatol Venereol. 2021;35(12):e846–7.
pubmed: 34363257
pmcid: 8447007
doi: 10.1111/jdv.17577
Ota M. SARS-CoV-2 mRNA vaccination and subsequent herpes zoster: possible immune reconstitution by mRNA vaccination. JAAD Case Rep. 2022. https://doi.org/10.1016/j.jdcr.2022.02.035 .
doi: 10.1016/j.jdcr.2022.02.035
pubmed: 35313557
pmcid: 8926427
Nishimoto M, Sogabe N, Hino M. Visceral disseminated varicella zoster virus infection following COVID-19 vaccination in an allogeneic stem cell transplant recipient. Transpl Infect Dis. 2022;24(2): e13810.
pubmed: 35213772
pmcid: 9115351
doi: 10.1111/tid.13810
Nastro F, et al. Small vessel vasculitis related to varicella-zoster virus after Pfizer-BioNTech COVID-19 vaccine. J Eur Acad Dermatol Venereol. 2021;35(11):e745–7.
pubmed: 34310759
pmcid: 8446985
doi: 10.1111/jdv.17550
Munasinghe BM, et al. Reactivation of varicella-zoster virus following mRNA COVID-19 vaccination in a patient with moderately differentiated adenocarcinoma of rectum: a case report. SAGE Open Med Case Rep. 2022. https://doi.org/10.1177/2050313X221077737 .
doi: 10.1177/2050313X221077737
pubmed: 36388638
pmcid: 9661556
Muhie OA, et al. Herpes zoster following covaxin receipt. Int Med Case Rep J. 2021;14:819–21.
pubmed: 34880682
pmcid: 8646222
doi: 10.2147/IMCRJ.S345288
Mishra SB, et al. Reactivation of varicella zoster infection presenting as acute retinal necrosis post COVID 19 vaccination in an asian indian male. Eur J Ophthalmol. 2021. https://doi.org/10.1177/11206721211046485 .
doi: 10.1177/11206721211046485
pubmed: 34541931
Medhat R, et al. Varicella-Zoster virus (VZV) meningitis in an immunocompetent adult after BNT162b2 mRNA COVID-19 vaccination: a case report. Int J Infect Dis. 2022;119:184–6.
pubmed: 35398296
pmcid: 9058432
doi: 10.1016/j.ijid.2022.04.001
Maruki T, et al. A case of varicella zoster virus meningitis following BNT162b2 mRNA COVID-19 vaccination in an immunocompetent patient. Int J Infect Dis. 2021;113:55–7.
pubmed: 34587536
pmcid: 8467371
doi: 10.1016/j.ijid.2021.09.055
Maranini B, et al. Herpes zoster infection following mRNA COVID-19 vaccine in a patient with ankylosing spondylitis. Reumatismo. 2021. https://doi.org/10.4081/reumatismo.2021.1445 .
doi: 10.4081/reumatismo.2021.1445
pubmed: 34814659
Maldonado MD, Romero-Aibar J. The Pfizer-BNT162b2 mRNA-based vaccine against SARS-CoV-2 may be responsible for awakening the latency of herpes varicella-zoster virus. Brain Behav Immun Health. 2021;18: 100381.
pubmed: 34746880
pmcid: 8556178
doi: 10.1016/j.bbih.2021.100381
Lv Y, Chang Y. Cytomegalovirus proctitis developed after COVID-19 vaccine: a case report and literature review. Vaccines (Basel). 2022. https://doi.org/10.3390/vaccines10091417 .
doi: 10.3390/vaccines10091417
pubmed: 36560490
Lo T, et al. Varicella zoster reactivation causing acute retinal necrosis following mrna covid-19 vaccination in a young immunocompetent man. Ocul Immunol Inflamm. 2022. https://doi.org/10.1080/09273948.2022.2033795 .
doi: 10.1080/09273948.2022.2033795
pubmed: 36166664
Lin TY, et al. Hemophagocytic lymphohistiocytosis following BNT162b2 mRNA COVID-19 vaccination. Vaccines (Basel). 2022. https://doi.org/10.3390/vaccines10040573 .
doi: 10.3390/vaccines10040573
pubmed: 36679862
pmcid: 9657784
Lim ZV, Kanagalingam J, Heng YK. Response to “Varicella-zoster virus reactivation after SARS- CoV-2 BNT162b2 mRNA vaccination: report of 5 cases.” JAAD Case Rep. 2022. https://doi.org/10.1016/j.jdcr.2021.09.044 .
doi: 10.1016/j.jdcr.2021.09.044
pubmed: 36017194
pmcid: 9396252
Li SQ, et al. Herpetic keratitis preceded by COVID-19 vaccination. Vaccines. 2021. https://doi.org/10.3390/vaccines9121394 .
doi: 10.3390/vaccines9121394
pubmed: 35062708
pmcid: 8779802
Koh S, et al. Varicella zoster virus reactivation in central and peripheral nervous systems following COVID-19 vaccination in an immunocompetent patient. J Clin Neurol. 2022;18(1):99–101.
pubmed: 35021285
doi: 10.3988/jcn.2022.18.1.99
Kluger N, Klimenko T, Bosonnet S. Herpes simplex, herpes zoster and periorbital erythema flares after SARS-CoV-2 vaccination: 4 cases. Ann Dermatol Venereol. 2022;149(1):58–60.
pubmed: 34711399
doi: 10.1016/j.annder.2021.07.009
Kerr C, et al. Zoster meningitis in an immunocompetent young patient post first dose of BNT162b2 mRNA COVID-19 vaccine, a case report. IDCases. 2022;27: e01452.
pubmed: 35186672
pmcid: 8837498
doi: 10.1016/j.idcr.2022.e01452
Jiang ZH, et al. Disseminated and localised herpes zoster following Oxford-AstraZeneca COVID-19 vaccination. Indian J Dermatol Venereol Leprol. 2022;88(3):445.
pubmed: 35389012
doi: 10.25259/IJDVL_819_2021
Jeong J. Vestibular neuritis after COVID-19 vaccination. Hum Vaccin Immunother. 2021;17(12):5126–8.
pubmed: 34898387
pmcid: 8903955
doi: 10.1080/21645515.2021.2013085
Herzum A, et al. Epstein-Barr virus reactivation after COVID-19 vaccination in a young immunocompetent man: a case report. Clin Exp Vaccine Res. 2022;11(2):222–5.
pubmed: 35799871
pmcid: 9200649
doi: 10.7774/cevr.2022.11.2.222
Girardin FR, et al. Multifocal lymphadenopathies with polyclonal reactions primed after EBV infection in a mRNA-1273 vaccine recipient. Swiss Med Wkly. 2022;152: w30188.
pubmed: 35748061
doi: 10.4414/SMW.2022.w30188
Fukuoka H, et al. Oral herpes zoster infection following COVID-19 vaccination: a report of five cases. Cureus. 2021;13(11): e19433.
pubmed: 34909338
pmcid: 8663753
Eid E, et al. Herpes zoster emergence following mRNA COVID-19 vaccine. J Med Virol. 2021;93(9):5231–2.
pubmed: 33913545
pmcid: 8242521
doi: 10.1002/jmv.27036
Dermawan A, et al. Acute herpes zoster radiculopathy mimicking cervical radiculopathy after ChAdOx1 nCoV-19/AZD1222 vaccination. BMJ Case Rep. 2022. https://doi.org/10.1136/bcr-2022-248943 .
doi: 10.1136/bcr-2022-248943
pubmed: 35459652
pmcid: 9036357
Chiu HH, et al. Herpes zoster following COVID-19 vaccine: a report of three cases. QJM. 2021;114(7):531–2.
pubmed: 34293165
doi: 10.1093/qjmed/hcab208
Buranasakda M, et al. Varicella zoster meningitis following COVID-19 vaccination: a report of two cases. Int J Infect Dis. 2022. https://doi.org/10.1016/j.ijid.2022.03.055 .
doi: 10.1016/j.ijid.2022.03.055
pubmed: 35367355
pmcid: 8964532
Atiyat R, et al. Varicella-zoster virus reactivation in aids patient after pfizer-bioNTech COVID-19 vaccine. Cureus. 2021;13(12): e20145.
pubmed: 35003978
pmcid: 8723776
Arora P, et al. Herpes zoster after inactivated COVID-19 vaccine: A cutaneous adverse effect of the vaccine. J Cosmet Dermatol. 2021;20(11):3389–90.
pubmed: 34077622
pmcid: 8242496
doi: 10.1111/jocd.14268
Ardalan M, et al. Herpes-like skin lesion after AstraZeneca vaccination for COVID-19: a case report. Clin Case Rep. 2021;9(10): e04883.
pubmed: 34631069
pmcid: 8489397
doi: 10.1002/ccr3.4883
Alkhalifah MI, et al. Herpes simplex virus keratitis reactivation after SARS-CoV-2 BNT162b2 mRNA vaccination: a report of two cases. Ocul Immunol Inflamm. 2021;29(6):1238–40.
pubmed: 34637667
doi: 10.1080/09273948.2021.1986548
Algaadi SA. Herpes zoster after COVID-19 vaccine: A case report. Pak J Med Health Sci. 2021;15(3):1165–6.
Al-Dwairi RA, et al. Reactivation of herpes simplex keratitis on a corneal graft following SARS-CoV-2 mRNA vaccination. Med Arch. 2022;76(2):146–8.
pubmed: 35774041
pmcid: 9233471
doi: 10.5455/medarh.2022.76.146-148
Aksu SB, Öztürk GZ. A rare case of shingles after COVID-19 vaccine: is it a possible adverse effect? Clin Exp Vaccine Res. 2021;10(2):198–201.
pubmed: 34222134
doi: 10.7774/cevr.2021.10.2.198
Abu-Rumeileh S, et al. Varicella zoster virus-induced neurological disease after COVID-19 vaccination: a retrospective monocentric study. J Neurol. 2022;269(4):1751–7.
pubmed: 34724572
doi: 10.1007/s00415-021-10849-3
Alkwikbi H, et al. Herpetic keratitis and corneal endothelitis following COVID-19 vaccination: a case series. Cureus. 2022;14(1): e20967.
pubmed: 35154946
pmcid: 8815810
Almutairi N, et al. Herpes zoster in the era of COVID 19: A prospective observational study to probe the association of herpes zoster with COVID 19 infection and vaccination. Dermatol Ther. 2022;35(7): e15521.
pubmed: 35434963
pmcid: 9111648
doi: 10.1111/dth.15521
Chakravorty S, et al. CMV infection following mRNA SARS-CoV-2 vaccination in solid organ transplant recipients. Transplantation direct. 2022;8(7): e1344.
pubmed: 35706606
pmcid: 9191559
doi: 10.1097/TXD.0000000000001344
Chew MC, et al. Incidence of COVID-19 vaccination-related uveitis and effects of booster dose in a tertiary uveitis referral center. Front Med. 2022;9: 925683.
doi: 10.3389/fmed.2022.925683
Furer V, et al. Herpes zoster following BNT162b2 mRNA COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series. Rheumatology (Oxford). 2021. https://doi.org/10.1093/rheumatology/keab345 .
doi: 10.1093/rheumatology/keab345
pubmed: 34554242
Job AM, et al. Herpes zoster following vaccination with ChAdOx1 nCoV-19 Coronavirus vaccine (recombinant). Indian J Public Health. 2022;66(1):83–5.
pubmed: 35381724
doi: 10.4103/ijph.ijph_2017_21
Monastirli A, et al. Herpes zoster after mRNA COVID-19 vaccination: a case series. Skinmed. 2022;20(4):284–8.
pubmed: 35976017
Psichogiou M, et al. Reactivation of varicella zoster virus after vaccination for SARS-CoV-2. Vaccines (Basel). 2021. https://doi.org/10.3390/vaccines9060572 .
doi: 10.3390/vaccines9060572
pubmed: 34579254
Rodríguez-Jiménez P, et al. Varicella-zoster virus reactivation after SARS-CoV-2 BNT162b2 mRNA vaccination: report of 5 cases. JAAD Case Rep. 2021;12:58–9.
pubmed: 33937467
pmcid: 8071473
doi: 10.1016/j.jdcr.2021.04.014
Saraiva AL, et al. Varicella zoster virus reactivation following COVID-19 vaccination: a report of 3 cases. Fam Pract. 2022. https://doi.org/10.1093/fampra/cmac014 .
doi: 10.1093/fampra/cmac014
pubmed: 35244157
Zhang Z, et al. Cytomegalovirus reactivation in immunocompetent mechanical ventilation patients: a prospective observational study. BMC Infect Dis. 2021;21(1):1026.
pubmed: 34592936
pmcid: 8482357
doi: 10.1186/s12879-021-06698-0
Tang WR, et al. A case report of posttransplant lymphoproliferative disorder after astrazeneca coronavirus disease 2019 vaccine in a heart transplant recipient. Transplant Proc. 2021. https://doi.org/10.1016/j.transproceed.2021.09.006 .
doi: 10.1016/j.transproceed.2021.09.006
pubmed: 34702598
pmcid: 8481090
Daouk SK, et al. Zoster meningitis in an immunocompetent child after COVID-19 Vaccination, California, USA. Emerg Infect Dis. 2022;28(7):1523–4.
pubmed: 35680126
pmcid: 9239884
doi: 10.3201/eid2807.220600
Grinde B. Herpesviruses: latency and reactivation - viral strategies and host response. J Oral Microbiol. 2013. https://doi.org/10.3402/jom.v5i0.22766 .
doi: 10.3402/jom.v5i0.22766
pubmed: 24167660
pmcid: 3809354
Traylen CM, et al. Virus reactivation: a panoramic view in human infections. Future Virol. 2011;6(4):451–63.
pubmed: 21799704
pmcid: 3142679
doi: 10.2217/fvl.11.21
Amon W, Farrell PJ. Reactivation of Epstein-Barr virus from latency. Rev Med Virol. 2005;15(3):149–56.
pubmed: 15546128
doi: 10.1002/rmv.456
Mendelson M, et al. Detection of endogenous human cytomegalovirus in CD34+ bone marrow progenitors. J Gen Virol. 1996;77(Pt 12):3099–102.
pubmed: 9000102
doi: 10.1099/0022-1317-77-12-3099
Yoshikawa T, et al. The characteristic site-specific reactivation phenotypes of HSV-1 and HSV-2 depend upon the latency-associated transcript region. J Exp Med. 1996;184(2):659–64.
pubmed: 8760819
doi: 10.1084/jem.184.2.659
Stoeger T, Adler H. “Novel” triggers of herpesvirus reactivation and their potential health relevance. Front Microbiol. 2018;9:3207.
pubmed: 30666238
doi: 10.3389/fmicb.2018.03207
Seneff S, et al. Innate immune suppression by SARS-CoV-2 mRNA vaccinations: the role of G-quadruplexes, exosomes, and MicroRNAs. Food Chem Toxicol. 2022;164: 113008.
pubmed: 35436552
pmcid: 9012513
doi: 10.1016/j.fct.2022.113008
Liu J, et al. Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines. Cell Discov. 2021;7(1):99.
pubmed: 34697287
pmcid: 8546144
doi: 10.1038/s41421-021-00329-3
Kolumam GA, et al. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med. 2005;202(5):637–50.
pubmed: 16129706
pmcid: 2212878
doi: 10.1084/jem.20050821
Desai HD, et al. Can SARS-CoV-2 vaccine increase the risk of reactivation of Varicella zoster? A systematic review J Cosmet Dermatol. 2021;20(11):3350–61.
pubmed: 34719084
doi: 10.1111/jocd.14521
Martinez-Reviejo R, et al. Varicella-Zoster virus reactivation following severe acute respiratory syndrome coronavirus 2 vaccination or infection: new insights. Eur J Intern Med. 2022;104:73–9.
pubmed: 35931613
pmcid: 9340059
doi: 10.1016/j.ejim.2022.07.022
Musialik J, Kolonko A, Więcek A. Increased EBV DNAemia after Anti-SARS-CoV-2 vaccination in solid organ transplants. Vaccines. 2022. https://doi.org/10.3390/vaccines10070992 .
doi: 10.3390/vaccines10070992
pubmed: 35891156
pmcid: 9325163